Cargando…

The digestive system involvement of antiphospholipid syndrome: pathophysiology, clinical characteristics, and treatment strategies

Antiphospholipid syndrome (APS) is an autoimmune disease mainly characterised by vascular thrombosis and pregnancy morbidity. APS has broad spectrum of clinical manifestations. The digestive system involvement of antiphospholipid syndrome is a critical but under-recognised condition. Digestive syste...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jin, Li, Cheng, Han, Xiaorong, Chen, Zhongbo, Adhikari, Binay Kumar, Wang, Yinghui, Wang, Yonggang, Sun, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381908/
https://www.ncbi.nlm.nih.gov/pubmed/34409894
http://dx.doi.org/10.1080/07853890.2021.1962964
_version_ 1783741452073828352
author Zhang, Jin
Li, Cheng
Han, Xiaorong
Chen, Zhongbo
Adhikari, Binay Kumar
Wang, Yinghui
Wang, Yonggang
Sun, Jian
author_facet Zhang, Jin
Li, Cheng
Han, Xiaorong
Chen, Zhongbo
Adhikari, Binay Kumar
Wang, Yinghui
Wang, Yonggang
Sun, Jian
author_sort Zhang, Jin
collection PubMed
description Antiphospholipid syndrome (APS) is an autoimmune disease mainly characterised by vascular thrombosis and pregnancy morbidity. APS has broad spectrum of clinical manifestations. The digestive system involvement of antiphospholipid syndrome is a critical but under-recognised condition. Digestive system involvement may be the result of direct (autoimmune-mediated) or indirect (thrombotic) mechanisms. Liver is the most commonly involved organ, followed by intestines, oesophagus, stomach, pancreas and spleen. This review describes possible digestive system manifestations in APS patients, and illustrates the epidemiology and possible pathophysiology of APS. The role of different treatment strategies in the management of digestive system manifestations of APS were also discussed. KEY MESSAGES: Antiphospholipid syndrome is a multi-organ, multi-system disease and its clinical manifestation spectrum is gradually expanding. Since the first diagnosis of APS, the clinical manifestations of digestive system have been reported successively. This narrative review describes the major digestive system manifestations of APS and illustrates the epidemiology, pathophysiology and the role of therapeutic strategies of these patients.
format Online
Article
Text
id pubmed-8381908
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-83819082021-08-24 The digestive system involvement of antiphospholipid syndrome: pathophysiology, clinical characteristics, and treatment strategies Zhang, Jin Li, Cheng Han, Xiaorong Chen, Zhongbo Adhikari, Binay Kumar Wang, Yinghui Wang, Yonggang Sun, Jian Ann Med Rheumatology Antiphospholipid syndrome (APS) is an autoimmune disease mainly characterised by vascular thrombosis and pregnancy morbidity. APS has broad spectrum of clinical manifestations. The digestive system involvement of antiphospholipid syndrome is a critical but under-recognised condition. Digestive system involvement may be the result of direct (autoimmune-mediated) or indirect (thrombotic) mechanisms. Liver is the most commonly involved organ, followed by intestines, oesophagus, stomach, pancreas and spleen. This review describes possible digestive system manifestations in APS patients, and illustrates the epidemiology and possible pathophysiology of APS. The role of different treatment strategies in the management of digestive system manifestations of APS were also discussed. KEY MESSAGES: Antiphospholipid syndrome is a multi-organ, multi-system disease and its clinical manifestation spectrum is gradually expanding. Since the first diagnosis of APS, the clinical manifestations of digestive system have been reported successively. This narrative review describes the major digestive system manifestations of APS and illustrates the epidemiology, pathophysiology and the role of therapeutic strategies of these patients. Taylor & Francis 2021-08-19 /pmc/articles/PMC8381908/ /pubmed/34409894 http://dx.doi.org/10.1080/07853890.2021.1962964 Text en © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Rheumatology
Zhang, Jin
Li, Cheng
Han, Xiaorong
Chen, Zhongbo
Adhikari, Binay Kumar
Wang, Yinghui
Wang, Yonggang
Sun, Jian
The digestive system involvement of antiphospholipid syndrome: pathophysiology, clinical characteristics, and treatment strategies
title The digestive system involvement of antiphospholipid syndrome: pathophysiology, clinical characteristics, and treatment strategies
title_full The digestive system involvement of antiphospholipid syndrome: pathophysiology, clinical characteristics, and treatment strategies
title_fullStr The digestive system involvement of antiphospholipid syndrome: pathophysiology, clinical characteristics, and treatment strategies
title_full_unstemmed The digestive system involvement of antiphospholipid syndrome: pathophysiology, clinical characteristics, and treatment strategies
title_short The digestive system involvement of antiphospholipid syndrome: pathophysiology, clinical characteristics, and treatment strategies
title_sort digestive system involvement of antiphospholipid syndrome: pathophysiology, clinical characteristics, and treatment strategies
topic Rheumatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381908/
https://www.ncbi.nlm.nih.gov/pubmed/34409894
http://dx.doi.org/10.1080/07853890.2021.1962964
work_keys_str_mv AT zhangjin thedigestivesysteminvolvementofantiphospholipidsyndromepathophysiologyclinicalcharacteristicsandtreatmentstrategies
AT licheng thedigestivesysteminvolvementofantiphospholipidsyndromepathophysiologyclinicalcharacteristicsandtreatmentstrategies
AT hanxiaorong thedigestivesysteminvolvementofantiphospholipidsyndromepathophysiologyclinicalcharacteristicsandtreatmentstrategies
AT chenzhongbo thedigestivesysteminvolvementofantiphospholipidsyndromepathophysiologyclinicalcharacteristicsandtreatmentstrategies
AT adhikaribinaykumar thedigestivesysteminvolvementofantiphospholipidsyndromepathophysiologyclinicalcharacteristicsandtreatmentstrategies
AT wangyinghui thedigestivesysteminvolvementofantiphospholipidsyndromepathophysiologyclinicalcharacteristicsandtreatmentstrategies
AT wangyonggang thedigestivesysteminvolvementofantiphospholipidsyndromepathophysiologyclinicalcharacteristicsandtreatmentstrategies
AT sunjian thedigestivesysteminvolvementofantiphospholipidsyndromepathophysiologyclinicalcharacteristicsandtreatmentstrategies
AT zhangjin digestivesysteminvolvementofantiphospholipidsyndromepathophysiologyclinicalcharacteristicsandtreatmentstrategies
AT licheng digestivesysteminvolvementofantiphospholipidsyndromepathophysiologyclinicalcharacteristicsandtreatmentstrategies
AT hanxiaorong digestivesysteminvolvementofantiphospholipidsyndromepathophysiologyclinicalcharacteristicsandtreatmentstrategies
AT chenzhongbo digestivesysteminvolvementofantiphospholipidsyndromepathophysiologyclinicalcharacteristicsandtreatmentstrategies
AT adhikaribinaykumar digestivesysteminvolvementofantiphospholipidsyndromepathophysiologyclinicalcharacteristicsandtreatmentstrategies
AT wangyinghui digestivesysteminvolvementofantiphospholipidsyndromepathophysiologyclinicalcharacteristicsandtreatmentstrategies
AT wangyonggang digestivesysteminvolvementofantiphospholipidsyndromepathophysiologyclinicalcharacteristicsandtreatmentstrategies
AT sunjian digestivesysteminvolvementofantiphospholipidsyndromepathophysiologyclinicalcharacteristicsandtreatmentstrategies